2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-172461
    MAO-IN-6 98%
    MAO-IN-6 (Compound 3f) is a BBB permeable and reversible MAO-B inhibitor with an IC50 of 0.09 μM. MAO-IN-6 also exhibits certain inhibitory activities against AChE and BChE, with IC50 values of 4.48 μM and 17.03 μM, respectively. MAO-IN-6 has low cytotoxicity and can be used in the research of Alzheimer's disease.
    MAO-IN-6
  • HY-172529
    DPP9-IN-1 3020859-03-1
    DPP9-IN-1 (Compound 42) is a dipeptidyl peptidase 9 (DPP9) inhibitor with IC50 of 3 nM for DPP9 and 0.6 μM for DPP8. DPP9-IN-1 induces concentration-dependent LDH release in THP-1 cells.
    DPP9-IN-1
  • HY-172530
    Heptanoyl-coenzyme A tetrasodium
    Heptanoyl-coenzyme A (Heptanoyl-CoA) tetrasodium is a derivative of CoA. Heptanoyl-coenzyme A tetrasodium is an inhibitor of butyryl-CoA acetate-CoA transferase (BUT) and inhibits butyric acid synthesis. Heptanoyl-coenzyme A tetrasodium blocks the improvements in motor function induced by the isoquinoline alkaloid Berberine (HY-N0716).
    Heptanoyl-coenzyme A tetrasodium
  • HY-172531
    Sulfonadyn-47 3064686-59-2 98%
    Sulfonadyn-47 is a GTP-competitive dynamin I (dynI) inhibitor that targets the active site in the GTPase domain of dynamin I, with IC50 values of 3.5 μM against dynI, 27.3 μM in clathrin-mediated endocytosis (CME) assays, and 12.3 μM in synaptic vesicle endocytosis (SVE) assays. Sulfonadyn-47 increases seizure threshold. Sulfonadyn-47 can be used the study for the seizure.
    Sulfonadyn-47
  • HY-172532
    Acetylagmatine acetate 2108663-32-5 98%
    Acetylagmatine (N-Acetylagmatine) acetate is a product formed by agmatine N-acetyltransferase (AgmNAT) catalyzing the reaction of acetyl-CoA and Agmatine (HY-101238). Agmatine is the product of arginine decarboxylation. Agmatine is a neurotransmitter and neuromodulator in mammalian brain.
    Acetylagmatine acetate
  • HY-172539
    N,N-Diformylmescaline
    N,N-Diformylmescaline is a analogue of Mescaline.
    N,N-Diformylmescaline
  • HY-172542
    TTBK1/2-IN-1 2342571-09-7 98%
    TTBK1/2-IN-1 (compound 3) is a potent Tau tubulin kinase 1 (TTBK1) and TTBK2 inhibitor with IC50s of 816 nM and 384 nM, respectively.
    TTBK1/2-IN-1
  • HY-172543
    TTBK1/2-IN-2 2857982-35-3 98%
    TTBK1/2-IN-2 (compound 9) is a potent Tau tubulin kinase 1 (TTBK1) and TTBK2 inhibitor with IC50s of 384 nM and 175 nM, respectively. TTBK1/2-IN-2 shows a significant ciliogenesis phenotype in human induced pluripotent stem cells (iPSCs).
    TTBK1/2-IN-2
  • HY-172547
    3-p-FBT hydrochloride
    3-p-FBT (hydrochloride) (3b-FBT (hydrochloride); Fluorotropacocaine (hydrochloride)) is an analytical reference standard that is structurally categorized as a tropane alkaloid.
    3-p-FBT hydrochloride
  • HY-172560
    6β-Oxycodol N-oxide
    6β-Oxycodol N-oxide is an opioid derivative and a metabolite of Oxycodone, which can be detected in urine.
    6β-Oxycodol N-oxide
  • HY-172568
    (±)5(6)-EET Ethanolamide
    (±)5(6)-EET Ethanolamide is a metabolite of Anandamide (HY-10863) generated via oxidation by cytochrome P450 enzymes. (±)5(6)-EET Ethanolamide is also a selective cannabinoid receptor 2 (CB2) agonist. (±)5(6)-EET Ethanolamide has Ki values of 11.4 μM and 8.9 nM for human CB1 and CB2, respectively . (±)5(6)-EET Ethanolamide can be used in research on immunomodulation and neuroinflammation.
    (±)5(6)-EET Ethanolamide
  • HY-172574
    8-iso-17-Phenyl trinor prostaglandin F2α
    8-Iso-17-phenyl trinor prostaglandin F2α (8-Iso-17-phenyl trinor PGF2), the C-8 epimer of Bimatoprost (HY-B0191), is a PGF2α (HY-12956) analog. Bimatoprost can be used in the research of glaucoma and high intraocular pressure.
    8-iso-17-Phenyl trinor prostaglandin F2α
  • HY-172583
    Neuroprotective agent 9 2757093-41-5 98%
    Neuroprotective agent 9 (compound 7) is a neuroprotective agent. Neuroprotective agent 9 is promising for research of neuron injury such as cerebral apoplexy, cerebral injury, and neuropathic pain.
    Neuroprotective agent 9
  • HY-172584
    Kv7.2/Kv7.3 modulator-1 2981435-42-9 98%
    Kv7.2/Kv7.3 modulator-1 (compound 6a) is a Kv7.2/Kv7.3 modulator with the pEC50 of 7.96 (KV7.2/3 channel opening activity). Kv7.2/Kv7.3 modulator-1 can be used for study of epilepsy, depression,brain injury and pain.
    Kv7.2/Kv7.3 modulator-1
  • HY-172585
    Kv7.2/Kv7.3 modulator-2 98%
    Kv7.2/Kv7.3 modulator-2 (compound 7d) is a Kv7.2/Kv7.3 modulator with the pEC50 of 7.42 (KV7.2/3 channel opening activity). Kv7.2/Kv7.3 modulator-2 can be used for study of epilepsy, depression,brain injury and pain.
    Kv7.2/Kv7.3 modulator-2
  • HY-172586
    GSK-3α/β-IN-1 1574354-24-7 98%
    GSK-3α/β-IN-1 is GSK-3α/β inhibitor with IC50 s of 0.265 μM and 0.255 μM for GSK-3α and GSK-3β, respectively. GSK-3α/β-IN-1 also inhibits PKA with an IC50 of 0.188 μM. GSK-3α/β-IN-1 potently inhibits cell viability of three Glioblastoma (GBM) cell lines (IC50 : 3-6 μM, 72 h) with no toxicity to human astrocytes and good metabolic stability. GSK-3α/β-IN-1 has potential CNS activity in all-human blood-brain barrier (BBB) model of GBM.
    GSK-3α/β-IN-1
  • HY-172588
    GABAA receptor modulator-7 98%
    GABAA receptor modulator-7 (compound 1m), a spiro-Barbiturate, is a GABAA receptor modulator. GABAA receptor modulator-7 reverses the action of anesthetics without affecting GABA-induced desensitization and can be used for study of antiepileptics and anxiolytics.
    GABAA receptor modulator-7
  • HY-172599
    GSK-3β probe-1 98%
    GSK-3β probe-1 (10c) is a GSK-3β probe (Ex = 341 nm, Em= 574nm, ɛ= 3.51 × 104L/mol·cm−1) and can be be used in the study of Alzheimer's disease.
    GSK-3β probe-1
  • HY-172604
    Neuroprotective agent 10 98%
    Neuroprotective agent 10 is an orally active, blood-brain barrier permeable neuroprotective agent. Neuroprotective agent 10 scavenges ABTS, DPPH and superoxide anion free radicals. Neuroprotective agent 10 inhibits abnormal electrical discharges. At the cellular level, Neuroprotective agent 10 alleviates H2O2-induced oxidative damage and LPS (HY-D1056)-induced neuroinflammation, and relieves epileptic symptoms and oxidative damage in mice. Neuroprotective agent 10 can be used in the research of epilepsy.
    Neuroprotective agent 10
  • HY-172620
    LIB3S0280 99.89%
    LIB3S0280 is a potent TBK1 inhibitor with an IC50 value of 493.9 nM. LIB3S0280 exhibits better anticancer effects in pancreatic cancer cell lines with high TBK1 expression. LIB3S0280 inhibits TBK1 downstream signaling pathways, including PI3K/AKT and NF-κB. LIB3S0280 induces G2/M arrest, apoptosis and cellular senescence. LIB3S0280 can be used for pancreatic ductal adenocarcinoma (PDAC) research.
    LIB3S0280
Cat. No. Product Name / Synonyms Application Reactivity